Cancer Immunotherapy Market
Cancer Immunotherapy Market Analysis By Therapy (Monoclonal Antibody, Immune Checkpoint Inhibitors, Immune System Modulators), By Type (Lung, Colorectal, Breast, Prostate, Melanoma, Blood Cancer), By End User, By Region - Global Insights to 2031
Analysis of Cancer Immunotherapy market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Table of Content
1. Preface 1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary : Global Cancer Immunotherapy Market 4. Market Overview 4.1. Introduction 4.1.1. Market Definition 4.1.2. Industry Evolution / Developments 4.2. Overview 4.3. Key Market Indicators 4.3.1. Region/Country Specific 4.3.2. Product/Therapeutic Area Specific 4.3.3. Target Market Specific – Global Scenario 4.4. Market Dynamics 4.4.1. Drivers 4.4.2. Restraints 4.4.3. Opportunity 4.4.4. Trends 4.5. Global Cancer Immunotherapy Market Analysis and Forecasts, 2021–2031 4.5.1. Market Revenue Projections (US$ Mn) 4.6. Cancer Immunotherapy Market - Global Supply Demand Scenario 4.7. Porter’s Five Force Analysis 4.8. Value Chain Analysis 4.8.1. List of active market participants 4.8.1.1. Manufacturers 4.8.1.2. Distributors 4.8.2. Forward – Backward Integration Scenario 4.9. Market Outlook 4.10. Pipeline Snapshot 4.11. Cancer Epidemiology 4.12. Reimbursement Scenario and Patient Support Programs Overview 5. Global Cancer Immunotherapy Market Analysis and Forecasts, By Therapy Type 5.1. Introduction & Definition 5.2. Key Findings / Developments 5.3. Market Value Forecast By Therapy Type, 2021–2031 5.3.1. Monoclonal Antibodies 5.3.2. Immune Checkpoint Inhibitors 5.3.2.1. PD-1/PD-L1 5.3.2.2. CTLA-4 5.3.3. Immune System Modulators 5.3.4. Cancer Vaccines 5.3.5. Others 5.4. Market Attractiveness By Therapy 6. Global Cancer Immunotherapy Market Analysis and Forecasts, By End User 6.1. Introduction & Definition 6.2. Key Findings / Developments 6.3. Market Value Forecast By End User, 2021–2031 6.3.1. Hospitals 6.3.2. ASC's 6.3.3. Cancer Research Institutes 6.3.4. Clinics 6.4. Market Attractiveness By End User 7. Global Cancer Immunotherapy Market Analysis and Forecasts, By Therapeutic Area 7.1. Introduction & Definition 7.2. Key Findings / Developments 7.3. Market Value Forecast By Therapeutic Area, 2021–2031 7.3.1. Lung Cancer 7.3.2. Colorectal Cancer 7.3.3. Breast Cancer 7.3.4. Prostate Cancer 7.3.5. Melanoma 7.3.6. Blood Cancers 7.3.7. Others 7.4. Market Attractiveness By Therapeutic Area 8. Global Cancer Immunotherapy Market Analysis and Forecasts, By Region 8.1. Key Findings 8.2. Policies and Regulations 8.3. Market Value Forecast By Region 8.3.1. North America 8.3.2. Europe 8.3.3. Asia Pacific 8.3.4. Latin America 8.3.5. Middle East and Africa 8.4. Market Attractiveness By Region 9. North America Cancer Immunotherapy Market Analysis and Forecast 9.1. Introduction 9.1.1. Key Findings 9.1.2. Policies and Regulations 9.2. Market Value Forecast By Therapy Type, 2021–2031 9.2.1. Monoclonal Antibodies 9.2.2. Immune Checkpoint Inhibitors 9.2.2.1. PD-1/PD-L1 9.2.2.2. CTLA-4 9.2.3. Immune System Modulators 9.2.4. Cancer Vaccines 9.2.5. Others 9.3. Market Value Forecast By End User, 2021–2031 9.3.1. Hospitals 9.3.2. ASC's 9.3.3. Cancer Research Institutes 9.3.4. Clinics 9.4. Market Value Forecast By Therapeutic Area, 2021–2031 9.4.1. Lung Cancer 9.4.2. Colorectal Cancer 9.4.3. Breast Cancer 9.4.4. Prostate Cancer 9.4.5. Melanoma 9.4.6. Blood Cancer 9.4.7. Others 9.5. Market Value Forecast By Country, 2021–2031 9.5.1. U.S. 9.5.2. Canada 9.6. Market Attractiveness Analysis 9.6.1. By Therapy Type 9.6.2. By End User 9.6.3. By Therapeutic Area 9.6.4. By Country 10. Europe Cancer Immunotherapy Market Analysis and Forecast 10.1. Introduction 10.1.1. Key Findings 10.1.2. Policies and Regulations 10.2. Market Value Forecast By Therapy Type, 2021–2031 10.2.1. Monoclonal Antibodies 10.2.2. Immune Checkpoint Inhibitors 10.2.2.1. PD-1/PD-L1 10.2.2.2. CTLA-4 10.2.3. Immune System Modulators 10.2.4. Cancer Vaccines 10.2.5. Others 10.3. Market Value Forecast By End User, 2021–2031 10.3.1. Hospitals 10.3.2. ASC's 10.3.3. Cancer Research Institutes 10.3.4. Clinics 10.4. Market Value Forecast By Therapeutic Area, 2021–2031 10.4.1. Lung Cancer 10.4.2. Colorectal Cancer 10.4.3. Breast Cancer 10.4.4. Prostate Cancer 10.4.5. Melanoma 10.4.6. Blood Cancer 10.4.7. Others 10.5. Market Value Forecast By Country, 2021–2031 10.5.1. Germany 10.5.2. U.K. 10.5.3. France 10.5.4. Spain 10.5.5. Italy 10.5.6. Rest of Europe 10.6. Market Attractiveness Analysis 10.6.1. By Therapy Type 10.6.2. By End User 10.6.3. By Therapeutic Area 10.6.4. By Country 11. Asia Pacific Cancer Immunotherapy Market Analysis and Forecast 11.1. Introduction 11.1.1. Key Findings 11.1.2. Policies and Regulations 11.2. Market Value Forecast By Therapy Type, 2021–2031 11.2.1. Monoclonal Antibodies 11.2.2. Immune Checkpoint Inhibitors 11.2.2.1. PD-1/PD-L1 11.2.2.2. CTLA-4 11.2.3. Immune System Modulators 11.2.4. Cancer Vaccines 11.2.5. Others 11.3. Market Value Forecast By End User, 2021–2031 11.3.1. Hospitals 11.3.2. ASC's 11.3.3. Cancer Research Institutes 11.3.4. Clinics 11.4. Market Value Forecast By Therapeutic Area, 2021–2031 11.4.1. Lung Cancer 11.4.2. Colorectal Cancer 11.4.3. Breast Cancer 11.4.4. Prostate Cancer 11.4.5. Melanoma 11.4.6. Blood Cancer 11.4.7. Others 11.5. Market Value Forecast By Country, 2021–2031 11.5.1. Japan 11.5.2. China 11.5.3. India 11.5.4. Australia 11.5.5. New Zealand 11.5.6. Rest of APAC 11.6. Market Attractiveness Analysis 11.6.1. By Therapy Type 11.6.2. By End User 11.6.3. By Therapeutic Area 11.6.4. By Country 12. Latin America Cancer Immunotherapy Market Analysis and Forecast 12.1. Introduction 12.1.1. Key Findings 12.1.2. Policies and Regulations 12.2. Market Value Forecast By Therapy Type, 2021–2031 12.2.1. Monoclonal Antibodies 12.2.2. Immune Checkpoint Inhibitors 12.2.2.1. PD-1/PD-L1 12.2.2.2. CTLA-4 12.2.3. Immune System Modulators 12.2.4. Cancer Vaccines 12.2.5. Others 12.3. Market Value Forecast By End User, 2021–2031 12.3.1. Hospitals 12.3.2. ASC's 12.3.3. Cancer Research Institutes 12.3.4. Clinics 12.4. Market Value Forecast By Therapeutic Area, 2021–2031 12.4.1. Lung Cancer 12.4.2. Colorectal Cancer 12.4.3. Breast Cancer 12.4.4. Prostate Cancer 12.4.5. Melanoma 12.4.6. Blood Cancer 12.4.7. Others 12.5. Market Value Forecast By Country, 2021–2031 12.5.1. Brazil 12.5.2. Mexico 12.5.3. Rest of Latin America 12.6. Market Attractiveness Analysis 12.6.1. By Therapy Type 12.6.2. By End User 12.6.3. By Therapeutic Area 12.6.4. By Country 13. Middle East and Africa Cancer Immunotherapy Market Analysis and Forecast 13.1. Introduction 13.1.1. Key Findings 13.1.2. Policies and Regulations 13.2. Market Value Forecast By Therapy Type, 2021–2031 13.2.1. Monoclonal Antibodies 13.2.2. Immune Checkpoint Inhibitors 13.2.2.1. PD-1/PD-L1 13.2.2.2. CTLA-4 13.2.3. Immune System Modulators 13.2.4. Cancer Vaccines 13.2.5. Others 13.3. Market Value Forecast By End User, 2021–2031 13.3.1. Hospitals 13.3.2. ASC's 13.3.3. Cancer Research Institutes 13.3.4. Clinics 13.4. Market Value Forecast By Therapeutic Area, 2021–2031 13.4.1. Lung Cancer 13.4.2. Colorectal Cancer 13.4.3. Breast Cancer 13.4.4. Prostate Cancer 13.4.5. Melanoma 13.4.6. Blood Cancer 13.4.7. Others 13.5. Market Value Forecast By Country, 2021–2031 13.5.1. Saudi Arabia 13.5.2. UAE 13.5.3. South Africa 13.5.4. Rest of MEA 13.6. Market Attractiveness Analysis 13.6.1. By Therapy Type 13.6.2. By End User 13.6.3. By Therapeutic Area 13.6.4. By Country 14. Competition Landscape 14.1. Market Player – Competition Matrix (By Tier and Size of companies) 14.2. Market Share Analysis By Company (2015) 14.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy) 14.3.1. Amgen, Inc. 14.3.1.1. Overview 14.3.1.2. Financials 14.3.1.3. Recent Developments 14.3.1.4. Strategy 14.3.2. AstraZenca Plc 14.3.2.1. Overview 14.3.2.2. Financials 14.3.2.3. Recent Developments 14.3.2.4. Strategy 14.3.3. Bristol-Myers Squibb Company 14.3.3.1. Overview 14.3.3.2. Financials 14.3.3.3. Recent Developments 14.3.3.4. Strategy 14.3.4. Eli Lilly and Company 14.3.4.1. Overview 14.3.4.2. Financials 14.3.4.3. Recent Developments 14.3.4.4. Strategy 14.3.5. F.Hoffmann-La Roche Ltd. 14.3.5.1. Overview 14.3.5.2. Financials 14.3.5.3. Recent Developments 14.3.5.4. Strategy 14.3.6. GlaxoSmithKline Plc. 14.3.6.1. Overview 14.3.6.2. Financials 14.3.6.3. Recent Developments 14.3.6.4. Strategy 14.3.7. Janssen Biotech, Inc. 14.3.7.1. Overview 14.3.7.2. Financials 14.3.7.3. Recent Developments 14.3.7.4. Strategy 14.3.8. Merck & Co. 14.3.8.1. Overview 14.3.8.2. Financials 14.3.8.3. Recent Developments 14.3.8.4. Strategy 14.3.9. Novartis AG 14.3.9.1. Overview 14.3.9.2. Financials 14.3.9.3. Recent Developments 14.3.9.4. Strategy 14.3.10. Pfizer, Inc. 14.3.10.1. Overview 14.3.10.2. Financials 14.3.10.3. Recent Developments 14.3.10.4. Strategy 14.3.11. Sanofi 14.3.11.1. Overview 14.3.11.2. Financials 14.3.11.3. Recent Developments 14.3.11.4. Strategy 14.3.12. Spectrum Pharmaceuticals, Inc. 14.3.12.1. Overview 14.3.12.2. Financials 14.3.12.3. Recent Developments 14.3.12.4. Strategy 14.3.13. Takeda Pharmaceuticals 14.3.13.1. Overview 14.3.13.2. Financials 14.3.13.3. Recent Developments 14.3.13.4. Strategy
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 1: Global Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type, 2021–2031
Table 2: Global Cancer Immunotherapy Market Size (US$ Mn) Forecast, By Therapy Type (Immune Checkpoint Inhibitors), 2021–2031
Table 3: Global Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapeutic Area, 2021–2031
Table 4: Global Cancer Immunotherapy Market Size (US$ Mn) Forecast, by End-User, 2021–2031
Table 5: Global Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Region, 2021–2031
Table 6: North America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type, 2021–2031
Table 7: North America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type (Immune Checkpoint Inhibitors), 2021–2031
Table 8: North America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapeutic Area, 2021–2031
Table 9: North America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by End-User, 2021–2031
Table 10: North America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2021–2031
Table 11: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type, 2021–2031
Table 12: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type (Immune Checkpoint Inhibitors), 2021–2031
Table 13: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapeutic Area, 2021–2031
Table 14: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, by End-User, 2021–2031
Table 15: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2021–2031
Table 16: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2021–2031
Table 17: Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type, 2021–2031
Table 18: Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type (Immune Checkpoint Inhibitors), 2021–2031
Table 19: Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapeutic Area, 2021–2031
Table 20: Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, by End-User, 2021–2031
Table 21: Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2021–2031
Table 22: Latin America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type, 2021–2031
Table 23: Latin America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type (Immune Checkpoint Inhibitors), 2021–2031
Table 24: Latin America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapeutic Area, 2021–2031
Table 25: Latin America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by End-User, 2021–2031
Table 26: Latin America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2021–2031
Table 27: Middle East & Africa Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type, 2021–2031
Table 28: Middle East & Africa Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type (Immune Checkpoint Inhibitors), 2021–2031
Table 29: Middle East & Africa Cancer Immunotherapy Market Size (US$ Mn) Forecast, by End-User, 2021–2031
Table 30: Middle East & Africa Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2021–2031
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 1: Global Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031
Figure 2: Global Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2021 and 2031
Figure 3: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Monoclonal Antibodies, 2021–2031
Figure 4: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Immune Checkpoint Inhibitors, 2021–2031
Figure 5: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Immune System Modulators, 2021–2031
Figure 6: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Cancer Vaccines, 2021–2031
Figure 7: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Others, 2021–2031
Figure 8: Global Cancer Immunotherapy Market Attractiveness Analysis, by Therapy Type
Figure 9: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By PD-1/PD-L1 Type, 2021–2031
Figure 10: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By CTLA-4 Type, 2021–2031
Figure 11: Global Cancer Immunotherapy Market Attractiveness Analysis, by Therapy Type (Immune Checkpoint Inhibitors)
Figure 12: Global Cancer Immunotherapy Market Value Share Analysis, by Therapeutic Area, 2021 and 2031
Figure 13: Global Cancer Immunotherapy Market Attractiveness Analysis, by Therapeutic Area
Figure 14: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Lung Cancer, 2021–2031
Figure 15: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Colorectal Cancer, 2021–2031
Figure 16: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Breast Cancer, 2021–2031
Figure 17: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Prostate Cancer, 2021–2031
Figure 18: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Melanoma, 2021–2031
Figure 19: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Blood Cancers, 2021–2031
Figure 20: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Other Cancers, 2021–2031
Figure 21: Global Cancer Immunotherapy Market Value Share Analysis, by End-User, 2021 and 2031
Figure 22: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Hospitals, 2021–2031
Figure 23: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By ASC’s, 2021–2031
Figure 24: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Cancer Research Institutes, 2021–2031
Figure 25: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Clinics, 2021–2031
Figure 26: Global Cancer Immunotherapy Market Attractiveness Analysis, by End-User
Figure 27: Global Cancer Immunotherapy Market Value Share Analysis, by Region, 2021 and 2031
Figure 28: Global Cancer Immunotherapy Market Attractiveness Analysis, by Region
Figure 29: North America Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031
Figure 30: North America Cancer Immunotherapy Market Attractiveness Analysis By Country
Figure 31: North America Market Value Share Analysis, by Therapy Type, 2021 and 2031
Figure 32: North America Market Value Share Analysis, by Therapeutic Area, 2021 and 2031
Figure 33: North America Market Value Share Analysis, by End-User, 2021 and 2031
Figure 34: North America Market Value Share Analysis, by Country, 2021 and 2031
Figure 35: U.S. Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031
Figure 36: U.S. Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031
Figure 37: Canada Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031
Figure 38: Canada Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031
Figure 39: North America Cancer Immunotherapy Market Attractiveness by Therapy Type
Figure 40: North America Cancer Immunotherapy Market Attractiveness by Therapeutic Area
Figure 41: North America Cancer Immunotherapy Market Attractiveness by End-User
Figure 42: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031
Figure 43: Europe Cancer Immunotherapy Market Attractiveness Analysis by Country
Figure 44: Europe Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2021 and 2031
Figure 45: Europe Cancer Immunotherapy Market Value Share Analysis, by Therapeutic Area, 2021 and 2031
Figure 46: Europe Cancer Immunotherapy Market Value Share Analysis, by End-User, 2021 and 2031
Figure 47: Europe Cancer Immunotherapy Market Value Share Analysis, by Country, 2021 and 2031
Figure 48: Germany Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031
Figure 49: Germany Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031
Figure 50: U.K. Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031
Figure 51: U.K. Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031
Figure 52: France Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031
Figure 53: France Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031
Figure 54: Spain Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031
Figure 55: Spain Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031
Figure 56: Italy Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031
Figure 57: Italy Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031
Figure 58: Rest of Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031
Figure 59: Rest of Europe Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031
Figure 60: Europe Cancer Immunotherapy Market Attractiveness by Therapy Type
Figure 61: Europe Cancer Immunotherapy Market Attractiveness by Therapeutic Area
Figure 62: Europe Cancer Immunotherapy Market Attractiveness by End-User
Figure 63: Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031
Figure 64: Asia Pacific Cancer Immunotherapy Market Attractiveness Analysis, By Country
Figure 65: Asia Pacific Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2021 and 2031
Figure 66: Asia Pacific Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2021 and 2031
Figure 67: Asia Pacific Cancer Immunotherapy Market Value Share Analysis, by End-User, 2021 and 2031
Figure 68: Asia Pacific Cancer Immunotherapy Market Value Share Analysis, by Country, 2021 and 2031
Figure 69: Japan Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031
Figure 70: Japan Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031
Figure 71: China Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031
Figure 72: China Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031
Figure 73: India Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031
Figure 74: India Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031
Figure 75: Australia Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031
Figure 76: Australia Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031
Figure 77: New Zealand Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031
Figure 78: New Zealand Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031
Figure 79: Rest of Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031
Figure 80: Rest of Asia Pacific Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031
Figure 81: Asia Pacific Cancer Immunotherapy Market Attractiveness by Therapy Type
Figure 82: Asia Pacific Cancer Immunotherapy Market Attractiveness by Therapeutic Area
Figure 83: Asia Pacific Cancer Immunotherapy Market Attractiveness by End-User
Figure 84: Asia Pacific Cancer Immunotherapy Market Attractiveness by End-User
Figure 85: Latin America Cancer Immunotherapy Market Attractiveness Analysis by Country
Figure 86: Latin America Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2021 and 2031
Figure 87: Latin America Cancer Immunotherapy Market Value Share Analysis, by Therapeutic Area, 2021 and 2031
Figure 88: Latin America Cancer Immunotherapy Market Value Share Analysis, by End-User, 2021 and 2031
Figure 89: Latin America Cancer Immunotherapy Market Value Share Analysis, by Country, 2021 and 2031
Figure 90: Brazil Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031
Figure 91: Brazil Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031
Figure 92: Mexico Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031
Figure 93: Mexico Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031
Figure 94: Mexico Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031
Figure 95: Rest of Latin America Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031
Figure 96: Latin America Cancer Immunotherapy Market Attractiveness by Therapy Type
Figure 97: Latin America Cancer Immunotherapy Market Attractiveness by Therapeutic Area
Figure 98: Latin America Cancer Immunotherapy Market Attractiveness by End-User
Figure 99: Middle East & Africa Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031
Figure 100: Middle East & Africa Cancer Immunotherapy Market Attractiveness Analysis by Country
Figure 101: Middle East & Africa Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2021 and 2031
Figure 102: Middle East & Africa Cancer Immunotherapy Market Value Share Analysis, by Therapeutic Area, 2021 and 2031
Figure 103: Middle East & Africa Cancer Immunotherapy Market Value Share Analysis, by End-User, 2021 and 2031
Figure 104: Middle East & Africa Cancer Immunotherapy Market Value Share Analysis, by End-User, 2021 and 2031
Figure 105: Saudi Arabia Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031
Figure 106: Saudi Arabia Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031
Figure 107: UAE Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031
Figure 108: UAE Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031
Figure 109: RSA Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031
Figure 110: RSA Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031
Figure 111: Rest of Middle East & Africa Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031
Figure 112: Rest of Middle East & Africa Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031
Figure 113: Middle East & Africa Cancer Immunotherapy Market Attractiveness by Therapy Type
Figure 114: Middle East & Africa Cancer Immunotherapy Market Attractiveness by Therapeutic Area
Figure 115: Middle East & Africa Cancer Immunotherapy Market Attractiveness by End-User
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request